Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series
Baraliakos X et.al.; Clin Case Rep. 2022 Jan 20;10(1):e05205.
כל הפוסטים בArticle
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series
16:14
Vijayan S et.al.; Clin Case Rep. 2022 Jan 13;10(1):e05233
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
14:29
Westhovens et.al.; Rheumatology 2021;60:2277–2287
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
14:52
Schreiber et.al.; Gastroenterology 2021;160:2340–2353
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
15:07
Caporali et.al.; Expert Rev Clin Immunol 2021 Jan;17(1):85-99